Arrate Plazaola

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Emilio Alba, Lourdes Calvo, Joan Albanell et al. · Annals of Oncology · 2012 · 222 citations · Full text

Breast Oncology, Oncology, Phase-ii Study +5

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i> -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial

Luca Gianni, Mauro Mansutti, Antonio Antón et al. · JAMA Oncology · 2018 · 153 citations · Full text

A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma

Rámón Colomer, Mariano Monzó, Ignasi Tusquets et al. · Clinical Cancer Research · 2008 · 122 citations

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

Aleix Prat, Aňa Lluch, Joan Albanell et al. · British Journal of Cancer · 2014 · 110 citations · Full text

Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma

Salvador Martín‐Algarra, Enrique Espinosa, Jordi Rubió‐Casadevall et al. · European Journal of Cancer · 2009 · 85 citations

Surgical Oncology, Medicine, Melanoma +8